EP1311239A4 - Orale verabreichung von peptiden - Google Patents

Orale verabreichung von peptiden

Info

Publication number
EP1311239A4
EP1311239A4 EP00952034A EP00952034A EP1311239A4 EP 1311239 A4 EP1311239 A4 EP 1311239A4 EP 00952034 A EP00952034 A EP 00952034A EP 00952034 A EP00952034 A EP 00952034A EP 1311239 A4 EP1311239 A4 EP 1311239A4
Authority
EP
European Patent Office
Prior art keywords
peptide
oral delivery
oral
delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00952034A
Other languages
English (en)
French (fr)
Other versions
EP1311239A1 (de
Inventor
Hack-Joo Kim
Heung-Man An
Min-Jong Cha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hyundai Pharm Co Ltd
Original Assignee
Hyundai Pharmaceutical Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyundai Pharmaceutical Ind Co Ltd filed Critical Hyundai Pharmaceutical Ind Co Ltd
Publication of EP1311239A1 publication Critical patent/EP1311239A1/de
Publication of EP1311239A4 publication Critical patent/EP1311239A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EP00952034A 2000-08-11 2000-08-11 Orale verabreichung von peptiden Withdrawn EP1311239A4 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2000/000892 WO2002013782A1 (en) 2000-08-11 2000-08-11 Oral delivery of peptide

Publications (2)

Publication Number Publication Date
EP1311239A1 EP1311239A1 (de) 2003-05-21
EP1311239A4 true EP1311239A4 (de) 2005-06-22

Family

ID=19198254

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00952034A Withdrawn EP1311239A4 (de) 2000-08-11 2000-08-11 Orale verabreichung von peptiden

Country Status (6)

Country Link
EP (1) EP1311239A4 (de)
JP (1) JP2004506003A (de)
CN (1) CN1479609A (de)
AU (1) AU2000264796A1 (de)
CA (1) CA2420032A1 (de)
WO (1) WO2002013782A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6761901B1 (en) 2000-05-02 2004-07-13 Enzrel Inc. Liposome drug delivery
US6759058B1 (en) * 2001-04-25 2004-07-06 Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences Enteric-coated proliposomal formulations for poorly water soluble drugs
US8658202B2 (en) 2001-04-25 2014-02-25 Western University Of Health Sciences Coated drug delivery formulations
JP2005523249A (ja) 2002-01-09 2005-08-04 エンズレル インコーポレイテッド 多環式芳香族抗酸化剤または抗炎症化合物のリポソーム薬物配達
CN100371018C (zh) * 2003-06-12 2008-02-27 刘青松 降钙素组合物
JP4669665B2 (ja) * 2004-04-12 2011-04-13 正彦 阿部 細胞毒性のないポリカチオン修飾リポソームおよびその製造方法
WO2006062506A1 (en) * 2004-12-03 2006-06-15 Enzrel, Inc. Chitosan-coated liposome drug delivery of antioxidant or anti-inflammatory compounds
JP2008179563A (ja) * 2007-01-24 2008-08-07 Cosmo Shokuhin Kk 有用リン脂質組成物を含む機能性素材及び機能性食品
WO2009149537A1 (en) * 2008-06-12 2009-12-17 Christine Allen Injectable polymer-lipid blend
PT2442821T (pt) 2009-06-18 2017-09-29 Allergan Inc Administração segura de desmopressina
CN103127003B (zh) * 2013-03-19 2014-05-07 广东彼迪药业有限公司 一种奥美拉唑肠溶微丸、胶囊及其制备方法
CN105902400B (zh) * 2016-06-17 2019-10-11 四川百奥可生物科技有限责任公司 一种包裹生物酶的微粒及其制备方法和应用
CN114010801B (zh) * 2021-11-16 2023-09-26 上海理工大学 一种l-抗坏血酸棕榈酸酯修饰的小分子肽脂质体及其制备与应用
CN114081963B (zh) * 2021-11-16 2023-09-26 上海理工大学 一种提高活性肽生物利用度的纳米载体及其制备与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4615885A (en) * 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
EP0855179A2 (de) * 1997-01-16 1998-07-29 Lipotec, S.A. Pharmazeutische Zubereitung umfassend mit einem Überzug versehene Kapseln oder Tabletten enthaltende in einen Wirkstoff enthaltendes Liposomenpulver

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4615885A (en) * 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
EP0855179A2 (de) * 1997-01-16 1998-07-29 Lipotec, S.A. Pharmazeutische Zubereitung umfassend mit einem Überzug versehene Kapseln oder Tabletten enthaltende in einen Wirkstoff enthaltendes Liposomenpulver

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO0213782A1 *

Also Published As

Publication number Publication date
JP2004506003A (ja) 2004-02-26
AU2000264796A1 (en) 2002-02-25
CN1479609A (zh) 2004-03-03
CA2420032A1 (en) 2002-02-21
EP1311239A1 (de) 2003-05-21
WO2002013782A1 (en) 2002-02-21

Similar Documents

Publication Publication Date Title
EP1383518A4 (de) Orale abgabe von makromolekülen
EG23943A (en) Flash-melt oral dosage formulation
HUP0203204A3 (en) Oral dosage forms
PL367180A1 (en) Stabilized oral pharmaceutical composition
MXPA03004941A (es) Formulacion farmacologica que tiene tolerancia por via oral mejorada.
PL364621A1 (en) Nicotine-containing oral dosage form
EP1585503A4 (de) Verbesserte orale verabreichung von peptiden
EP1311239A4 (de) Orale verabreichung von peptiden
GB2383989B (en) Improved oral medicine dispenser
HUP0500638A3 (en) Flashmelt oral dosage formulation
SI1462455T1 (sl) Ser-Ser-Ser-Arg Peptid in zdravilna uporaba le-tega
AP2003002783A0 (en) Medicament containing activted antihtrombin iii
HUP0201667A3 (en) Oral form of administration
IL147731A0 (en) Peptide pharmaceutical formulations
AU2002239279A1 (en) Oral nanosphere delivery
EP1275657A4 (de) Peptid-derivate und medizinische zusammensetzungen
IL135442A0 (en) Peptides and pharmaceutical compositions comprising them
GB2361643B (en) Delivery capsules
PL362244A1 (en) Medicinal compositions
GB0021645D0 (en) Delivery of substances
EP1230928A4 (de) Verwendung von peptid
HK1047232A1 (zh) 口服劑型
IL136274A0 (en) Pharmaceutical compositions comprising vip-related peptides
IL138971A0 (en) Pharmaceutical compositions comprising vip-related peptides
GB0021927D0 (en) Use of pharmaceutical combination

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030211

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RBV Designated contracting states (corrected)

Designated state(s): BE DE ES FR GB IT

A4 Supplementary search report drawn up and despatched

Effective date: 20050506

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 9/28 B

Ipc: 7A 61K 9/20 B

Ipc: 7A 61K 9/127 A

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060301